Navigation Links
Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Date:3/10/2008

Company to host conference call Today, Monday, March 10, 2008 at 8:30am

NEW YORK, March 10 /PRNewswire-FirstCall/ -- On Friday, March 7, 2008, Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex (sulodexide) for the treatment of diabetic nephropathy. The Company announced that this Phase 3 clinical trial failed to meet the primary objective of the study, which was to increase the proportion of patients that achieve therapeutic success at 6 months as compared to placebo over background therapy of maximal doses of ACE-inhibitors or ARBs. Therapeutic success was defined as (i) conversion from microalbuminuria to normoalbuminuria, as measured by albumin/creatinine ratio (ACR), with at least a 25% reduction in ACR relative to baseline ACR, or (ii) a 50% reduction in ACR relative to baseline ACR. In addition, in reviewing the mean changes in ACR over time, Sulonex and placebo appeared to be similar.

Michael S. Weiss, the Company's Chairman and Chief Executive Officer, commented, "We are all very disappointed with the outcome of this Study. While this represents the end of one chapter for Keryx, it is not the end of Keryx. Drug development is inherently risky and, accordingly, we have spent the last several years building what we believe to be a promising product portfolio in the event our lead drug failed. We plan to re-focus our primary efforts and resources on rapidly moving Zerenex forward for ESRD patients with hyperphosphatemia and Perifosine forward for cancer. Our goal is to have Perifosine in a pivotal program this year and be well into our Zerenex high- dose Phase 2 trial before the end of the year."

In order to participate in this morning's c
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
3. Keryx Biopharmaceuticals Announces Additions to Management Team
4. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce ... Switzerland -based Kenta Biotech to acquire ... (mAb) products, and technologies. This asset portfolio purchase ... of infections by common pathogens including drug resistant ... Pseudomonas aeruginosa , Acinetobacter baumannii and ...
(Date:5/17/2013)... RURO Inc. is pleased to ... versatile refinement to the smart management solution. , ... advanced methodical management for transgenic animal colonies, genotyping ... network-based platform provides user access with a plethora ... to emphasize streamlined tasks, such as animal relocation ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 The ... by Global Cooling, Inc., Athens, OH, USA, won the ... by the International Society for Biological and Environmental Repositories ... award, given to one product annually, recognizes the company’s ... ultra-low temperature freezer. The award was presented to ...
(Date:5/16/2013)... Vernon Hills, Ill. (PRWEB) May 16, 2013 ... including benchtop and portable models, from Cole-Parmer is ... professionals. The enhanced line includes: , The new ... that are true workhorses in the lab. They ... superior serum and plasma specimen separation. Their standard ...
Breaking Biology Technology:Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2Cole-Parmer Offers Enhanced Selection of Centrifuges 2
... MIGENIX Inc. (the,"Company" or "MIGENIX") (TSX: MGI; ... infectious diseases, reports financial results for the ... a corporate update on its programs,and other ... Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic ...
... decades-old drug to beat atherosclerotic plaques in research conducted ... , The scientists have found that drug-laced nanoparticles plus ... vessels that feed arterial plaques. Their results suggest that ... their growth, which could shrink or stabilize plaques. Although ...
... safe supply of drinking water for regions of the ... is rife. Writing in the International Journal of ... nanotubes could replace conventional materials in water-purification systems. , ... water will continue to grow as major global problems. ...
Cached Biology Technology:MIGENIX Reports First Quarter Fiscal 2009 Financial Results 2MIGENIX Reports First Quarter Fiscal 2009 Financial Results 3MIGENIX Reports First Quarter Fiscal 2009 Financial Results 4MIGENIX Reports First Quarter Fiscal 2009 Financial Results 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 6MIGENIX Reports First Quarter Fiscal 2009 Financial Results 7MIGENIX Reports First Quarter Fiscal 2009 Financial Results 8MIGENIX Reports First Quarter Fiscal 2009 Financial Results 9MIGENIX Reports First Quarter Fiscal 2009 Financial Results 10MIGENIX Reports First Quarter Fiscal 2009 Financial Results 11Old and new therapies combine to tackle atherosclerosis 2Old and new therapies combine to tackle atherosclerosis 3Water purification down the nanotubes 2
(Date:5/16/2013)... The relationship between the heritable risk for schizophrenia ... Schizophrenia is commonly associated with cognitive impairments that ... reduced IQ may be linked to the risk ... may precede the onset of schizophrenia symptoms. Also, ... of people diagnosed with schizophrenia. , In a ...
(Date:5/16/2013)... extinct creature with ,scissor hand-like, claws in fossil records ... movie star. , The 505 million year old ... which is a distant ancestor of lobsters and scorpions, ... starring role as Edward Scissorhands - a movie about ... has scissors for hands. , Kooteninchela deppi ...
(Date:5/16/2013)... genome-wide analysis (GWA), where the entirety of an individual,s ... or variants which can cause health problems is a ... can also pose major ethical problems if used incorrectly, ... Genetics (ESHG) published on line today (16 May 2013) ... Many services based on whole genome and on exome* ...
Breaking Biology News(10 mins):Genetic risk for schizophrenia is connected to reduced IQ 2Actor Johnny Depp immortalized in ancient fossil find 2European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2
... The University of Queensland could contribute to the development ... and Dengue fever. Led by Associate Professor ... of Molecular and Microbial Sciences identified a novel characteristic ... The team found all flaviviruses produced a ...
... to a radical re-thinking about how the snowy owl ... the adult females that we followed in a satellite ... the Arctic sea ice," said Universit Laval doctoral student ... as part of an International Polar Year (IPY) research ...
... LANSING, Mich. --- Research by a Michigan State University ... way of developing protein-based drugs that are key to ... hepatitis. Proteins used in drug manufacture and research ... , a one-cell bacteria. That protein tends to collect ...
Cached Biology News:UQ research targets West Nile virus and dengue fever 2Snowy owl -- a marine species? 2
... (EMSA) is a powerful tool for evaluating ... shift or gel retardation, the assay is ... to electrophoresis, free DNA will migrate differently ... Chemiluminescent EMSA Kit is a nonradioactive system ...
... The Cytomics FC 500 ... family equipped with the most ... 500 Series delivers flexible testing, ... interface features that help researchers ...
... of a protein into cells permits studies ... pathways, apoptotic pathways, and transcription factor-mediated gene ... the effects of a specific protein in ... protein directly into the cell. ProteoJuice Protein ...
Reacti-Bind DNA Coating Solution...
Biology Products: